StocktoriaVivos Therapeutics, Inc. VVOS
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $17.4M | $15.0M | $13.8M | $16.0M | $16.9M |
| Gross profit | $10.5M | $9.0M | $8.3M | $10.0M | $12.6M |
| Operating income | -$19.9M | -$11.2M | -$17.3M | -$25.0M | -$20.4M |
| Net income | -$21.2M | -$11.1M | -$13.6M | -$23.8M | -$20.3M |
| Operating cash flow | -$15.3M | -$12.7M | -$11.9M | -$19.6M | -$15.7M |
| Free cash flow | -$17.6M | -$13.3M | -$12.7M | -$20.5M | -$18.1M |
| Total assets | $25.2M | $15.3M | $10.7M | $13.7M | $33.7M |
| Total liabilities | $26.7M | $7.3M | $10.3M | $8.9M | $8.2M |
| Shareholders' equity | -$1.5M | $8.0M | $411,000 | $4.8M | $25.5M |
| Ratios | |||||
| Gross margin | 60.4% | 60.0% | 59.9% | 62.5% | 74.6% |
| Operating margin | -114.1% | -74.3% | -125.3% | -156.2% | -120.7% |
| Net margin | -121.4% | -74.1% | -98.4% | -148.8% | -120.2% |
| FCF margin | -100.9% | -88.2% | -92.4% | -128.0% | -107.4% |
| Return on assets | -84.2% | -72.9% | -126.6% | -173.8% | -60.2% |
| Return on equity | 1420.8% | -140.0% | -3304.9% | -496.7% | -79.4% |
| Debt / equity | -0.51× | — | — | — | 0.05× |
| Current ratio | 0.24 | 1.50 | 0.34 | 0.80 | 3.64 |
| Revenue growth | 16.0% | 8.9% | -13.9% | -5.1% | 29.2% |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001716166 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.